Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal BIOCITY: Journal of Pharmacy Bioscience and Clinical Community
I Nengah Satria Wirananda
Universitas Bumigora
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Uji Validitas dan Reabilitas Kuesioner Naranjo untuk Mengukur Adverse Drug Reactions (ADRs)Pasien Aterosklerosis I Nengah Satria Wirananda; Fitri Apriliany; Novitarini
Biocity Journal of Pharmacy Bioscience and Clinical Community Vol 4 No 2 (2026): Biocity: Journal of Pharmacy Bioscience and Clinical Community
Publisher : Universitas Bumigora

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30812/biocity.v4i2.5842

Abstract

Patients with atherosclerosis receive concomitant cardiovascular medications, and the use of multiple medications can increase the risk of adverse drug reactions (ADRs). ADRs assessment is crucial to differentiate drug side effects from other conditions, like comorbidities, drug interactions, or environmental factors. ADRs are generally measured using the Naranjo algorithm questionnaire. The purpose of this study is to determine the validity and reliability of the Naranjo questionnaire for measuring ADRs in patients with atherosclerosis. This study used a non-experimental, descriptive-analytical design with a cross-sectional approach and prospective observation. The subjects in this study were 30 patients with atherosclerosis, and data were collected using the Naranjo algorithm questionnaire. The results showed that the Naranjo algorithm questionnaire was valid, as the content validity test yielded a Pearson Correlation coefficient of >0.361. This instrument was deemed reliable because its Cronbach’s alpha was>0.60. Therefore, the Indonesian version of the Naranjo algorithm questionnaire is valid and reliable, and can be used to measure adverse drug reactions in patients with atherosclerosis.
Co-Authors Fitri Apriliany, Fitri Novitarini